尼妥珠单抗治疗食管癌有效性和安全性的分析
发布时间：2018-12-29 16:43
【摘要】：目的系统评价尼妥珠单抗治疗食管癌的有效性和安全性。方法检索Medline、EMbase、Cochrane Library、Clinical Trials、中国生物医学文献数据库、相关期刊论文、维普和万方数据库,收集尼妥珠单抗治疗食管癌的临床试验,试验组予以尼妥珠单抗联合常规放化疗/化疗方案治疗,对照组予以常规放化疗/化疗方案治疗。用Rev Man 5.3对有效率、控制率、生存率和药物不良反应发生率等主要指标进行Meta分析。结果共纳入10项研究,共计535例患者。试验组和对照组的有效率分别为79.84%和65.96%;1年生存率分别为83.76%和67.13%;3年生存率分别为30.00%和14.29%;1年无进展生存率分别为85.26%和69.47%,差异均有统计学意义(均P0.05)。试验组和对照组的控制率分别为90.71%和79.88%;血液学毒性发生率分别为52.17%和50.95%;胃肠道反应发生率分别为31.90%和38.79%;放射性食管炎发生率分别为41.15%和36.17%;放射性肺炎发生率分别为15.82%和19.02%,差异均无统计学意义(均P0.05)。结论尼妥珠单抗对提高食管癌患者有效率并延长生存期有优势,且未增加药物不良反应的发生,可推荐联合放化疗/放疗用于食管癌患者治疗。
[Abstract]:Objective to evaluate the efficacy and safety of neytozumab in the treatment of esophageal carcinoma. Methods Medline,EMbase,Cochrane Library,Clinical Trials, Chinese Biomedical Literature Database, Chinese Journal Full-text Database, Weip and Wanfang databases were searched, and the clinical trials of Niytozumab in the treatment of esophageal carcinoma were collected. The experimental group was treated with niytozumab combined with conventional radiotherapy and chemotherapy, while the control group was treated with routine chemotherapy / radiotherapy. The effective rate, control rate, survival rate and incidence rate of adverse drug reactions were analyzed by Meta with Rev Man 5.3. Results A total of 535 patients were included in 10 studies. The effective rates of the two groups were 79.84% and 65.96%, the 1-year survival rates were 83.76% and 67.13%, the 3-year survival rates were 30.00% and 14.29%, respectively. The 1 year progression-free survival rate was 85.26% and 69.47%, respectively, and the difference was statistically significant (P0.05). The control rates of the test group and the control group were 90.71% and 79.88%, the incidence of hematological toxicity were 52.17% and 50.955%, the incidence of gastrointestinal reaction were 31.90% and 38.79%, respectively. The incidence of radiation esophagitis was 41.15% and 36.17%, and the incidence of radiation pneumonia was 15.82% and 19.02%, respectively. The difference was not significant (P0.05). Conclusion Niytozumab has advantages in improving the effective rate and prolonging the survival time of esophageal cancer patients, and does not increase the incidence of adverse drug reactions. It is recommended that combined radiotherapy and chemotherapy / radiotherapy should be used in the treatment of esophageal cancer patients.
【作者单位】： 首都医科大学附属北京世纪坛医院药剂科;北京大学药学院药事管理与临床药学系;
【分类号】：R735.1
本文编号：2395082
[Abstract]:Objective to evaluate the efficacy and safety of neytozumab in the treatment of esophageal carcinoma. Methods Medline,EMbase,Cochrane Library,Clinical Trials, Chinese Biomedical Literature Database, Chinese Journal Full-text Database, Weip and Wanfang databases were searched, and the clinical trials of Niytozumab in the treatment of esophageal carcinoma were collected. The experimental group was treated with niytozumab combined with conventional radiotherapy and chemotherapy, while the control group was treated with routine chemotherapy / radiotherapy. The effective rate, control rate, survival rate and incidence rate of adverse drug reactions were analyzed by Meta with Rev Man 5.3. Results A total of 535 patients were included in 10 studies. The effective rates of the two groups were 79.84% and 65.96%, the 1-year survival rates were 83.76% and 67.13%, the 3-year survival rates were 30.00% and 14.29%, respectively. The 1 year progression-free survival rate was 85.26% and 69.47%, respectively, and the difference was statistically significant (P0.05). The control rates of the test group and the control group were 90.71% and 79.88%, the incidence of hematological toxicity were 52.17% and 50.955%, the incidence of gastrointestinal reaction were 31.90% and 38.79%, respectively. The incidence of radiation esophagitis was 41.15% and 36.17%, and the incidence of radiation pneumonia was 15.82% and 19.02%, respectively. The difference was not significant (P0.05). Conclusion Niytozumab has advantages in improving the effective rate and prolonging the survival time of esophageal cancer patients, and does not increase the incidence of adverse drug reactions. It is recommended that combined radiotherapy and chemotherapy / radiotherapy should be used in the treatment of esophageal cancer patients.
【作者单位】： 首都医科大学附属北京世纪坛医院药剂科;北京大学药学院药事管理与临床药学系;
【分类号】：R735.1
【相似文献】
相关期刊论文 前5条
1 谭永才;程涛;;碘(~(131)I)美妥昔单抗治疗AFP升高1例[J];广东医学;2009年10期
2 刘玉琳;王军;;细胞免疫在单抗治疗肿瘤中的作用研究进展[J];现代免疫学;2011年01期
3 阮新建;王飞;宋飞翔;贾得前;;贝伐珠单抗治疗恶性肿瘤的相关不良反应及处理[J];中国医药导刊;2013年11期
4 倪凤明;姜新;马利新;黄祥;侯威;陈祥;曲雅勤;;放疗联合尼妥珠单抗治疗晚期复发直肠癌的疗效[J];中国老年学杂志;2014年07期
5 ;[J];;年期
相关重要报纸文章 前1条
1 美国食品药品管理局 欧盟药品管理局网站;贝伐珠单抗治疗乳腺癌风险评价研究引发广泛关注[N];中国医药报;2011年
，本文编号：2395082
本文链接：https://www.wllwen.com/yixuelunwen/zlx/2395082.html
